DOI: 10.1055/s-00000077

Seminars in Thrombosis and Hemostasis

LinksSchließen

Referenz

Bhatt DL, Topol EJ. , on behalf of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization Management and Avoidance Executive Committee
Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance (CHARISMA) trial 
Am Heart J 2004; 148: 263-268  

Bibliographische Angaben herunterladen

Suchen in:
Aufrufen in:
Aufrufen in: